Citations
1 publicationsPublications from researchers using this productDescription
Streptomycin is an effective antibiotic against Mycobacterium tuberculosis and is used in the study of tuberculosis (TB)[1]. Streptomycin acts as a protein synthesis inhibitor, binding irreversibly to the small 16S rRNA of the 30S ribosomal subunit, interfering with protein synthesis [2]. Streptomycin originally had broad Gram-negative and Gram-positive coverage, but its spectrum of activity has been significantly narrowed due to antibiotic resistance [3]. Streptomycin is an aminoglycoside antibacterial drug with poor oral absorption and can be administered intramuscularly or intravenously [4].
In vitro, treatment of guinea pig ventricular myocytes with streptomycin (40 μM) for 2 min significantly inhibited the stretch-induced increase in Ca2+. The decrease in Ca2+ occurred 18 seconds after the application of streptomycin (n=13 cells). In all cells, the decrease in Ca2+ occurred in less than 60 seconds, indicating that streptomycin has a calcium homeostatic effect on cardiomyocytes [5]. Streptomycin (5, 50μg/ml) can effectively inhibit the survival and proliferation of Mycobacterium tuberculosis in human macrophages infected with Mycobacterium tuberculosis[6].
In vivo, Streptomycin (50-100 mg/kg) was used to treat mice infected with Mycobacterium avium complex (MAC) by intramuscular injection for 4 weeks, which significantly reduced the MAC bacterial load in the spleen and liver, and showed partial protection in histopathological examination, but did not completely eliminate the infection. The liposome encapsulation effect of Streptomycin was better than that of the free form[7].
References:
[1] Cohen K A, Stott K E, Munsamy V, et al. Evidence for expanding the role of streptomycin in the management of drug-resistant Mycobacterium tuberculosis[J]. Antimicrobial agents and chemotherapy, 2020, 64(9): 10.1128/aac. 00860-20.
[2] Weisblum B, Davies J. Antibiotic inhibitors of the bacterial ribosome[J]. Bacteriological reviews, 1968, 32(4_pt_2): 493-528.
[3] Guardabassi L, Courvalin P. Modes of antimicrobial action and mechanisms of bacterial resistance[J]. Antimicrobial resistance in bacteria of animal origin, 2005: 1-18.
[4] EDSON R S, TERRELL C L. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, and sisomicin[C]//Mayo Clinic Proceedings. Elsevier, 1987, 62(10): 916-920.
[5] Gannier F, White E, Lacampagne A, et al. Streptomycin reverses a large stretch induced increase in [Ca2+] i in isolated guinea pig ventricular myocytes[J]. Cardiovascular research, 1994, 28(8): 1193-1198.
[6] Crowle A J, Sbarbaro J A, Judson F N, et al. Inhibition by streptomycin of tubercle bacilli within cultured human macrophages[J]. American Review of Respiratory Disease, 1984, 130(5): 839-844.
[7] Gangadharam P R J, Ashtekar D A, Ghori N, et al. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice[J]. Journal of Antimicrobial Chemotherapy, 1991, 28(3): 425-435.
Protocol
| Cell experiment [1]: | |
|
Cell lines |
Guinea pig ventricular myocytes |
|
Preparation Method |
Ventricular myocytes were treated with 40µM Streptomycin for 2 minutes to apply mechanical stretch to the cells to simulate the mechanical stress during cardiac contraction and relaxation. Changes in intracellular Ca2+ concentration were recorded at different time points. |
|
Reaction Conditions |
40μM; 2min |
|
Applications |
Application of streptomycin to this sensitive cell rapidly reversed the increase in Ca2+. The decrease in Ca2+ occurred 18 seconds after application of streptomycin (n = 13 cells). In all cells, the decrease in Ca2+ occurred in less than 60 seconds. |
| Animal experiment [2]: | |
|
Animal models |
Beige mice |
|
Preparation Method |
Beige mice were injected with Mycobacterium avium complex (MAC) suspension via the tail vein to establish a systemic infection model. Two doses(50-100 mg/kg) of free streptomycin, were given daily intramuscularly (im), five days a week for four weeks. In comparison, the drug encapsulated in large multilaminar liposomes was investigated at 5, 10 and15 mg/kb dose and administered iv only in two doses at day 1 and day 7 following the infection. Control groups received buffer, buffer-loaded d vesicles or free streptomycin given iv (15 mg/kg) every week for the four week durat tion. |
|
Dosage form |
100mg/kg; i.m. |
|
Applications |
Streptomycin exhibits significant antibacterial effects against MAC infection in beige mice, with liposome-encapsulated Streptomycin being more effective in reducing bacterial load and tissue lesions. |
|
References: [1] Gannier F, White E, Lacampagne A, et al. Streptomycin reverses a large stretch induced increase in [Ca2+] i in isolated guinea pig ventricular myocytes[J]. Cardiovascular research, 1994, 28(8): 1193-1198. [2]Gangadharam P R J, Ashtekar D A, Ghori N, et al. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice[J]. Journal of Antimicrobial Chemotherapy, 1991, 28(3): 425-435. |
|
Product Documents
Chemical Properties
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
Reviews
Review for Streptomycin
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%
